CoChat
Sign Up
Cited by 1,201Cancer Mechanisms and TherapyCancer Immunotherapy and BiomarkersCancer therapeutics and mechanisms

Exploring treatment options in cancer: tumor treatment strategies

Open access
Liu, Beilei, Zhou, Hongyu, Tan, Licheng, Siu, Kin To Hugo, Guan, Xin-Yuan·2024·Signal Transduction and Targeted Therapy
DOI 10.1038/s41392-024-01856-7PMC PMC11252281
Open this paper in CoChat — free account

Abstract

Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical and psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive and remarkable transformation. Emerging as fervently pursued modalities are small molecule targeted agents, antibody-drug conjugates (ADCs), cell-based therapies, and gene therapy. These cutting-edge treatment modalities not only afford personalized and precise tumor targeting, but also provide patients with enhanced therapeutic comfort and the potential to impede disease progression. Nonetheless, it is acknowledged that these therapeutic strategies still harbour untapped potential for further advancement. Gaining a comprehensive understanding of the merits and limitations of these treatment modalities holds the promise of offering novel perspectives for clinical practice and foundational research endeavours. In this review, we discussed the different treatment modalities, including small molecule targeted drugs, peptide drugs, antibody drugs, cell therapy, and gene therapy. It will provide a detailed explanation of each method, addressing their status of development, clinical challenges, and potential solutions. The aim is to assist clinicians and researchers in gaining a deeper understanding of these diverse treatment options, enabling them to carry out effective treatment and advance their research more efficiently.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-024-01856-7

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Preclinical studies have demonstrated efficacy of phages targeting Fusobacterium nucleatum.

    “Preclinical studies have demonstrated the efficacy of phages targeting Fusobacterium nucleatum [64,65]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [64]

    The section “New drugs based on the impact of gut microbiota on tumor progression” (page unavailable) discusses bacteria and cancer treatment but does not mention Fusobacterium nucleatum or phage efficacy. Searches for the species, phages, and bacteriophage therapy found no passage in our copy reporting the claimed preclinical result. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 436

  1. [3]Frankel, R. I. Centennial of Röntgen’s discovery of x-rays. West. J. Med. 164, 497–501 (1996). 8764624 PMC1303625
  2. [4]Steinberg, F. M. & Raso, J. Biotech pharmaceuticals and biotherapy: an overview. J. Pharm. Pharm. Sci. 1, 48–59 (1998). 10945918
  3. [6]Grillo-López, A. J. et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol. 1, 1–9 (2000). 11467356 10.2174/1389201003379059 · DOI
  4. [7]Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101–126 (2023). 36344672 10.1038/s41573-022-00579-0 PMC9640784 · DOI · Paper page
  5. [8]Sun, X. et al. Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination. Cell Death Dis. 14, 839 (2023). 38110356 10.1038/s41419-023-06300-2 PMC10728200 · DOI
  6. [9]Sun, C., Gao, W., Liu, J., Cheng, H. & Hao, J. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir. Res. 21, 210 (2020). 32778129 10.1186/s12931-020-01477-y PMC7418324 · DOI
  7. [10]Carter, J. & Tadi, P. Erlotinib. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2024). 32119371
  8. [11]Tewari, K. S. et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390, 1654–1663 (2017). 28756902 10.1016/S0140-6736(17)31607-0 PMC5714293 · DOI
  9. [12]Hietanen, E., Koivu, M. K. A. & Susi, P. Cytolytic properties and genome analysis of Rigvir® Oncolytic Virotherapy virus and other Echovirus 7 Isolates. Viruses 14, 525 (2022). 35336934 10.3390/v14030525 PMC8949920 · DOI
  10. [13]Sun, H. et al. TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC. Cell Death Dis. 13, 450 (2022). 35546143 10.1038/s41419-022-04909-3 PMC9095598 · DOI
  11. [14]Myers, R. M. et al. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T cells in CAR-Naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 39, 3044–3055 (2021). 10.1200/JCO.20.03458 PMC9851702 34156874 · DOI
  12. [15]Bouffet, Eric et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 mutations. N. Engl. J. Med. 389, 1108–1120 (2023). 37733309 10.1056/NEJMoa2303815 · DOI
  13. [17]Harrington, K. J. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the Phase III KEYNOTE-048 Study. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 41, 790–802 (2023). 10.1200/JCO.21.02508 PMC9902012 36219809 · DOI
  14. [18]Joura Elmar, A. et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N. Engl. J. Med. 372, 711–723 (2015). 25693011 10.1056/NEJMoa1405044 · DOI · Paper page
  15. [19]Zhang, T. et al. Talimogene Laherparepvec (T-VEC): A review of the recent advances in cancer therapy. J. Clin. Med. 12, 1098 (2023). 36769745 10.3390/jcm12031098 PMC9917711 · DOI
  16. [20]Todo, T. et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 1630–1639 (2022). 35864254 10.1038/s41591-022-01897-x PMC9388376 · DOI
  17. [22]Finn, R. S. et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020). 32402160 10.1056/NEJMoa1915745 · DOI · Paper page
  18. [23]Durante, M., Debus, J. & Loeffler, J. S. Physics and biomedical challenges of cancer therapy with accelerated heavy ions. Nat. Rev. Phys. 3, 777–790 (2021). 34870097 10.1038/s42254-021-00368-5 PMC7612063 · DOI
  19. [25]Falzone, L., Salomone, S. & Libra, M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018). 30483135 10.3389/fphar.2018.01300 PMC6243123 · DOI
  20. [26]Lemberg, K. M., Gori, S. S., Tsukamoto, T., Rais, R. & Slusher, B. S. Clinical development of metabolic inhibitors for oncology. J. Clin. Invest. 132, e148550 (2022). 34981784 10.1172/JCI148550 PMC8718137 · DOI
  21. [27]Moreno, C., Muñoz, C., Terol, M. J., Hernández-Rivas, J.-Á. & Villanueva, M. Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. J. Exp. Clin. Cancer Res. 40, 321 (2021). 34654437 10.1186/s13046-021-02115-1 PMC8517318 · DOI
  22. [28]Sliwoski, G., Kothiwale, S., Meiler, J. & Lowe, E. W. Computational methods in drug discovery. Pharmacol. Rev. 66, 334–395 (2014). 24381236 10.1124/pr.112.007336 PMC3880464 · DOI
  23. [29]Benjin, X. & Ling, L. Developments, applications, and prospects of cryo‐electron microscopy. Protein Sci. Publ. Protein Soc. 29, 872–882 (2020). 10.1002/pro.3805 PMC7096719 31854478 · DOI
  24. [30]Tsukamoto, Y. et al. 150-kD oxygen-regulated protein is expressed in human atherosclerotic plaques and allows mononuclear phagocytes to withstand cellular stress on exposure to hypoxia and modified low density lipoprotein. J. Clin. Invest. 98, 1930–1941 (1996). 8878445 10.1172/JCI118994 PMC507633 · DOI
  25. [31]Hu, Y. et al. NMR-based methods for protein analysis. Anal. Chem. 93, 1866–1879 (2021). 33439619 10.1021/acs.analchem.0c03830 · DOI
  26. [32]Banerjee, A., Bhakta, S. & Sengupta, J. Integrative approaches in cryogenic electron microscopy: Recent advances in structural biology and future perspectives. iScience 24, 102044 (2021). 33532719 10.1016/j.isci.2021.102044 PMC7829201 · DOI
  27. [33]Dhakal, A., Gyawali, R., Wang, L. & Cheng, J. A large expert-curated cryo-EM image dataset for machine learning protein particle picking. Sci. Data 10, 392 (2023). 37349345 10.1038/s41597-023-02280-2 PMC10287764 · DOI
  28. [34]Skalidis, I. et al. Cryo-EM and artificial intelligence visualize endogenous protein community members. Struct. Lond. Engl. 30, 575–589.e6 (2022). 35093201
  29. [35]Al-Azzawi, A., Ouadou, A., Tanner, J. J. & Cheng, J. AutoCryoPicker: An unsupervised learning approach for fully automated single particle picking in Cryo-EM images. BMC Bioinforma. 20, 326 (2019). 10.1186/s12859-019-2926-y PMC6567647 31195977 · DOI
  30. [36]Yu, H., Ma, H., Yang, K., Zhao, Y. & Jin, Y. DeepEM: Deep Neural Networks Model Recovery through EM Side-Channel Information Leakage. in 2020 IEEE International Symposium on Hardware Oriented Security and Trust (HOST) 209–218 (2020). 10.1109/HOST45689.2020.9300274. · DOI
  31. [37]Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol. Res. 187, 106552 (2023). 36403719 10.1016/j.phrs.2022.106552 · DOI
  32. [38]Iqbal, N. & Iqbal, N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother. Res. Pract. 2014, 1–9 (2014). 10.1155/2014/357027 PMC4055302 24963404 · DOI
  33. [39]Karnoub, A. E. & Weinberg, R. A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517–531 (2008). 18568040 10.1038/nrm2438 PMC3915522 · DOI · Paper page
  34. [42]Ferdinandos, S. et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl. J. Med. 384, 2371–2381 (2021). PMC9116274 34096690
  35. [43]Araujo, L. H. et al. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer. BMC Cancer 21, 193 (2021). 33632153 10.1186/s12885-021-07884-8 PMC7905642 · DOI
  36. [44]Qiu, J., Chen, K., Zhong, C., Zhu, S. & Ma, X. Network-based protein-protein interaction prediction method maps perturbations of cancer interactome. PLOS Genet. 17, e1009869 (2021). 34727106 10.1371/journal.pgen.1009869 PMC8610286 · DOI
  37. [47]Hansen, A. L., Xiang, X., Yuan, C., Bruschweiler-Li, L. & Brüschweiler, R. Excited-state observation of active K-Ras reveals differential structural dynamics of wild-type versus oncogenic G12D and G12C mutants. Nat. Struct. Mol. Biol. 30, 1446–1455 (2023). 37640864 10.1038/s41594-023-01070-z PMC10584678 · DOI
  38. [49]Lavoie, H., Gagnon, J. & Therrien, M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat. Rev. Mol. Cell Biol. 21, 607–632 (2020). 32576977 10.1038/s41580-020-0255-7 · DOI · Paper page
  39. [51]Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160–166 (2023). 37258666 10.1038/s41586-023-06123-3 PMC10322706 · DOI · Paper page
  40. [52]Changeux, J.-P. & Christopoulos, A. Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell 166, 1084–1102 (2016). 27565340 10.1016/j.cell.2016.08.015 · DOI
  41. [53]Hughes Timothy, P. et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase inhibitor failure. N. Engl. J. Med. 381, 2315–2326 (2019). 31826340 10.1056/NEJMoa1902328 PMC7724923 · DOI
  42. [54]Larkin, J. et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N. Engl. J. Med. 371, 1867–1876 (2014). 25265494 10.1056/NEJMoa1408868 · DOI
  43. [56]Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015). 26075522 10.1038/nchembio.1858 PMC4629852 · DOI · Paper page
  44. [57]Smith, A. R., Pucheault, M., Tae, H. S. & Crews, C. M. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg. Med. Chem. Lett. 18, 5904–5908 (2008). 18752944 10.1016/j.bmcl.2008.07.114 PMC3175619 · DOI · Paper page
  45. [58]Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M. & Cravatt, B. F. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Nat. Chem. Biol. 15, 737–746 (2019). 31209349 10.1038/s41589-019-0279-5 PMC6592777 · DOI · Paper page
  46. [60]Han, X. et al. Discovery of highly potent and efficient PROTAC degraders of Androgen Receptor (AR) by employing weak binding affinity VHL E3 Ligase ligands. J. Med. Chem. 62, 11218–11231 (2019). 31804827 10.1021/acs.jmedchem.9b01393 · DOI
  47. [61]Zhao, Q., Lan, T., Su, S. & Rao, Y. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem. Commun. Camb. Engl. 55, 369–372 (2019). 10.1039/C8CC07813K 30540295 · DOI
  48. [64]Rathkopf, D. E. et al. First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 42, 134 (2024).37972343 10.1200/JCO.2024.42.4_suppl.134 · DOI
  49. [67]Petrylak, D. P. et al. A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 41, TPS290 (2023). 10.1200/JCO.2023.41.6_suppl.TPS290 · DOI
  50. [68]Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer | Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-protacr-protein-degrader-arv.
  51. [69]Lloyd, M. R., Wander, S. A., Hamilton, E., Razavi, P. & Bardia, A. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther. Adv. Med. Oncol. 14, 17588359221113694 (2022). 35923930 10.1177/17588359221113694 PMC9340905 · DOI
  52. [70]Mato, A. R. et al. NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-targeted protein degrader, in patients with relapsed or refractory chronic Lymphocytic Leukemia and B-cell malignancies. Blood 140, 2329–2332 (2022). 10.1182/blood-2022-164772 · DOI · Paper page
  53. [71]Robbins, D. W. et al. Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies. Blood 138, 2251 (2021). 10.1182/blood-2021-147473 · DOI
  54. [72]Wang, H. et al. P1219: BGB-16673, A BTK degrader, overcomes on-target resistance from btk inhibitors and presents sustainable long-term tumor regression in Lymphoma Xenograft Models. HemaSphere 7, e24358c2 (2023). 10.1097/01.HS9.0000971772.24358.c2 · DOI
  55. [73]Li, J. et al. Abstract CT128: Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies. Cancer Res 83, CT128 (2023). 10.1158/1538-7445.AM2023-CT128 · DOI
  56. [78]Gao, J., Li, H.-R., Jin, C., Jiang, J.-H. & Ding, J.-Y. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Clin. Transl. Oncol. Publ. Fed. Span. Oncol. Soc. Natl Cancer Inst. Mex. 21, 1287–1301 (2019). 30864018
  57. [79]Vecchio, I., Tornali, C., Bragazzi, N. L. & Martini, M. The Discovery of Insulin: An important milestone in the history of medicine. Front. Endocrinol. 9, 613 (2018). 10.3389/fendo.2018.00613 PMC6205949 30405529 · DOI
  58. [80]Bruce Merrifield. Solid Phase Synthesis, Nobel Lecture. (1984). 4027355
  59. [81]Li, J. & Zhu, Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol. Sin. 31, 1198–1207 (2010). 20694021 10.1038/aps.2010.120 PMC4002304 · DOI
  60. [82]Akbarian, M., Khani, A., Eghbalpour, S. & Uversky, V. N. Bioactive peptides: synthesis, sources, applications, and proposed mechanisms of action. Int. J. Mol. Sci. 23, 1445 (2022). 35163367 10.3390/ijms23031445 PMC8836030 · DOI
  61. [83]Jiang, L. et al. 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis. J. Biomed. Biotechnol. 2012, 368075 (2012). 22570527 10.1155/2012/368075 PMC3336217 · DOI
  62. [84]Breeman, W. A. P. et al. Radiolabelling DOTA-peptides with 68Ga. Eur. J. Nucl. Med. Mol. Imaging 32, 478–485 (2005). 15655678 10.1007/s00259-004-1702-y · DOI
  63. [85]Liu, Z. et al. Two 90 Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. Mol. Pharm. 8, 591–599 (2011). 21247151 10.1021/mp100403y · DOI
  64. [86]Hofman, M. S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet Lond. Engl.397, 797–804 (2021). 33581798
  65. [87]Lei, Z. et al. Novel peptide GX1 inhibits angiogenesis by specifically binding to transglutaminase-2 in the tumorous endothelial cells of gastric cancer. Cell Death Dis. 9, 579 (2018). PMC5962530 29785022
  66. [88]Chen, K. et al. Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature. Mol. Imaging Biol. 14, 96–105 (2012). 21360213 10.1007/s11307-011-0479-1 PMC3629956 · DOI
  67. [89]Jiang, J. et al. Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model. Bioorg. Med. Chem. Lett. 40, 127901 (2021). 33705912 10.1016/j.bmcl.2021.127901 · DOI
  68. [90]Dolgin, E. Radioactive drugs emerge from the shadows to storm the market. Nat. Biotechnol. 36, 1125–1127 (2018). 30520873 10.1038/nbt1218-1125 · DOI
  69. [91]Guha, M. Amgen swallows Onyx whole. Nat. Biotechnol. 31, 859–860 (2013). 24104731 10.1038/nbt1013-859 · DOI
  70. [92]Kaisary, A. V., Tyrrell, C. J., Peeling, W. B. & Griffiths, K. Comparison of LHRH Analogue (Zoladex) with Orchiectomy in patients with metastatic prostatic carcinoma. Br. J. Urol. 67, 502–508 (1991). 1828183 10.1111/j.1464-410X.1991.tb15195.x · DOI
  71. [93]Lamers, C. Overcoming the shortcomings of peptide-based therapeutics. Future Drug Discov. 4, FDD75 (2022). 10.4155/fdd-2022-0005 · DOI
  72. [94]Keating, G. M. Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-Cell lymphoma. Drugs 70, 1445–1476 (2010). 20614951 10.2165/11201110-000000000-00000 · DOI
  73. [95]Lu, R.-M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020). 31894001 10.1186/s12929-019-0592-z PMC6939334 · DOI
  74. [96]Swain, S. M. et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724–734 (2015). 25693012 10.1056/NEJMoa1413513 PMC5584549 · DOI · Paper page
  75. [97]Van Cutsem, E. et al. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J. Clin. Oncol. 29, 2011–2019 (2011). 21502544 10.1200/JCO.2010.33.5091 · DOI · Paper page
  76. [98]Rugo, H. S. et al. Margetuximab Versus Trastuzumab in patients with previously treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final overall survival results from a randomized Phase 3 trial. J. Clin. Oncol. 41, 198–205 (2023). 36332179 10.1200/JCO.21.02937 PMC9839304 · DOI
  77. [99]Cortés, J. et al. Pertuzumab Monotherapy after Trastuzumab-based treatment and subsequent reintroduction of Trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor Receptor 2–positive breast cancer. J. Clin. Oncol. 30, 1594–1600 (2012). 22393084 10.1200/JCO.2011.37.4207 · DOI
  78. [100]Goldstein, D. A. et al. First- and second-line Bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a united states–based cost-effectiveness analysis. J. Clin. Oncol. 33, 1112–1118 (2015). 25691669 10.1200/JCO.2014.58.4904 PMC4881313 · DOI
  79. [101]Townsend, W. et al. Obinutuzumab Versus Rituximab Immunochemotherapy in previously untreated iNHL: Final results from the GALLIUM Study. HemaSphere 7, e919 (2023). 37404773 10.1097/HS9.0000000000000919 PMC10317485 · DOI
  80. [103]Fisher, J. G. et al. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia 37, 2036–2049 (2023). 37528310 10.1038/s41375-023-01984-z PMC10539165 · DOI
  81. [104]Tawbi Hussein, A. et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N. Engl. J. Med. 386, 24–34 (2022). PMC9844513 34986285
  82. [105]Mathieu, L. et al. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. Oncologist26, 433–438 (2021). PMC8100557 33687763
  83. [106]McDermott, D., Haanen, J., Chen, T.-T., Lorigan, P. & O’Day, S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann. Oncol. 24, 2694–2698 (2013). 23942774 10.1093/annonc/mdt291 · DOI
  84. [107]Sangro, B. et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann. Oncol. 35, 448–457 (2024). 38382875
  85. [112]Desai, J. et al. Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress. J. Clin. Oncol. 38, TPS3146 (2020). 10.1200/JCO.2020.38.15_suppl.TPS3146 · DOI
  86. [113]Ascierto, P. A. et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Ann. Oncol. 28, v611–v612 (2017). 10.1093/annonc/mdx440.011 · DOI
  87. [115]Liu, Y. et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct. Target. Ther. 8, 1–42 (2023). 36882399 PMC9990587
  88. [116]Li, S. et al. IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy. Antib. Ther. 6, 240–252 (2023). PMC10576855 37846296
  89. [117]DeFrancesco, L. Pheast Therapeutics: Another bite at the apple. Nat. Biotechnol. 10.1038/d41587-023-00015-7. (2023) 37798475 · DOI
  90. [119]Chames, P., Van Regenmortel, M., Weiss, E. & Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220–233 (2009). 19459844 10.1111/j.1476-5381.2009.00190.x PMC2697811 · DOI · Paper page
  91. [120]Rodríguez-Nava, C. et al. Mechanisms of action and limitations of monoclonal antibodies and Single Chain Fragment Variable (scFv) in the treatment of cancer. Biomedicines 11, 1610 (2023). 37371712 10.3390/biomedicines11061610 PMC10295864 · DOI
  92. [121]Price, T. J. et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 15, 569–579 (2014). 24739896 10.1016/S1470-2045(14)70118-4 · DOI · Paper page
  93. [122]Lou, H. & Cao, X. Antibody variable region engineering for improving cancer immunotherapy. Cancer Commun. Lond. Engl. 42, 804–827 (2022). 10.1002/cac2.12330 PMC9456695 35822503 · DOI
  94. [123]Shimazaki, K. et al. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 14, 7367–7377 (2008). 10.1158/1078-0432.CCR-08-1016 PMC3109074 19010852 · DOI
  95. [124]Holliger, P. & Hudson, P. J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126–1136 (2005). 16151406 10.1038/nbt1142 · DOI
  96. [125]Alderson, R. F. et al. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). Bioconjug. Chem. 17, 410–418 (2006). 16536473 10.1021/bc0503521 · DOI
  97. [126]Peters, C. & Brown, S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep. 35, e00225 (2015). 26182432 10.1042/BSR20150089 PMC4613712 · DOI
  98. [127]De Taeye, S. W. et al. FcγR binding and ADCC Activity of human IgG Allotypes. Front. Immunol. 11, 740 (2020). 32435243 10.3389/fimmu.2020.00740 PMC7218058 · DOI
  99. [129]Takegawa, N. et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int. J. Cancer 141, 1682–1689 (2017). 28677116 10.1002/ijc.30870 · DOI
  100. [131]Jin, Y., Schladetsch, M. A., Huang, X., Balunas, M. J. & Wiemer, A. J. Stepping forward in antibody-drug conjugate development. Pharmacol. Ther. 229, 107917 (2022). 34171334 10.1016/j.pharmthera.2021.107917 PMC8702582 · DOI
  101. [132]Baah, S., Laws, M. & Rahman, K. M. Antibody–drug conjugates—a tutorial review. Molecules 26, 2943 (2021). 34063364 10.3390/molecules26102943 PMC8156828 · DOI
  102. [133]Tong, J. T. W., Harris, P. W. R., Brimble, M. A. & Kavianinia, I. An Insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules 26, 5847 (2021). 34641391 10.3390/molecules26195847 PMC8510272 · DOI
  103. [134]Ng, G., Spreter, T., Davies, R. & Wickman, G. ZW38, a Novel Azymetric bispecific CD19-directed CD3 T cell engager antibody drug conjugate with controlled T cell activation and improved B cell cytotoxicity. Blood 128, 1841 (2016). 10.1182/blood.V128.22.1841.1841 · DOI
  104. [135]Andreev, J. et al. Bispecific antibodies and Antibody–Drug Conjugates (ADCs) bridging HER2 and Prolactin Receptor improve efficacy of HER2 ADCs. Mol. Cancer Ther. 16, 681–693 (2017). 28108597 10.1158/1535-7163.MCT-16-0658 · DOI
  105. [136]Sellmann, C. et al. Balancing selectivity and efficacy of bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET antibodies and antibody-drug conjugates. J. Biol. Chem. 291, 25106–25119 (2016). 27694443 10.1074/jbc.M116.753491 PMC5122778 · DOI
  106. [137]Sadiki, A. et al. Site-specific conjugation of native antibody. Antib. Ther. 3, 271–284 (2020). 33644685 PMC7906296
  107. [138]Samantasinghar, A. et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed. Pharmacother. 161, 114408 (2023). 36841027 10.1016/j.biopha.2023.114408 · DOI
  108. [139]Amani, N., Dorkoosh, F. A. & Mobedi, H. ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies. Curr. Drug Deliv. 17, 23–51 (2020). 31755387 10.2174/1567201816666191121145109 · DOI
  109. [140]Tarantino, P., Ricciuti, B., Pradhan, S. M. & Tolaney, S. M. Optimizing the safety of antibody–drug conjugates for patients with solid tumours. Nat. Rev. Clin. Oncol. 20, 558–576 (2023). 37296177 10.1038/s41571-023-00783-w · DOI · Paper page
  110. [142]Tokarew, N., Ogonek, J., Endres, S., Von Bergwelt-Baildon, M. & Kobold, S. Teaching an old dog new tricks: next-generation CAR T cells. Br. J. Cancer 120, 26–37 (2019). 30413825 10.1038/s41416-018-0325-1 PMC6325111 · DOI
  111. [143]Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021). 33483715 10.1038/s41568-020-00323-z PMC8353572 · DOI · Paper page
  112. [145]Hirabayashi, K. et al. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904–918 (2021). 34746799 10.1038/s43018-021-00244-2 PMC8570569 · DOI
  113. [147]Cronk, R. J., Zurko, J. & Shah, N. N. Bispecific chimeric antigen receptor T cell therapy for B cell malignancies and multiple myeloma. Cancers 12, 2523 (2020). 32899464 10.3390/cancers12092523 PMC7564024 · DOI
  114. [148]Spiegel, J. Y. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27, 1419–1431 (2021). 34312556 10.1038/s41591-021-01436-0 PMC8363505 · DOI
  115. [149]Gardner, R. A. et al. Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity. J. Clin. Oncol. 38, 3035 (2020). 10.1200/JCO.2020.38.15_suppl.3035 · DOI
  116. [150]Chen, X. et al. CD19/BCMA dual-targeting Fastcar-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s Lymphoma: An update. Blood 142, 6847 (2023). 10.1182/blood-2023-185476 · DOI
  117. [151]Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26, 1569–1575 (2020). 33020647 10.1038/s41591-020-1081-3 · DOI · Paper page
  118. [152]Dai, H. et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J. Hematol. Oncol. J. Hematol. Oncol. 13, 30 (2020). 32245502 10.1186/s13045-020-00856-8 PMC7126394 · DOI
  119. [153]Tong, C. et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood136, 1632–1644 (2020). PMC7596761 32556247
  120. [154]Kotch, C., Barrett, D. & Teachey, D. T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev. Clin. Immunol. 15, 813–822 (2019). 31219357 10.1080/1744666X.2019.1629904 PMC7936577 · DOI
  121. [155]Bajwa, A. K. et al. Efficacy of Siltuximab for chimeric antigen receptor T-cell therapy toxicities - a multicenter retrospective analysis. Blood 142, 4502 (2023). 10.1182/blood-2023-179620 · DOI
  122. [156]Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018). 29385370 10.1056/NEJMoa1709866 PMC5996391 · DOI · Paper page
  123. [157]Fitzgerald, J. C. et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med. 45, e124–e131 (2017). 27632680 10.1097/CCM.0000000000002053 PMC5452983 · DOI
  124. [158]Jaeger, U. et al. Portia: A Phase 1b study evaluating safety and efficacy of Tisagenlecleucel and Pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood 134, 5325 (2019). 10.1182/blood-2019-129120 · DOI
  125. [159]Choy, E. H. et al. Translating IL-6 biology into effective treatments. Nat. Rev. Rheumatol. 16, 335–345 (2020). 32327746 10.1038/s41584-020-0419-z PMC7178926 · DOI
  126. [160]Hamilton, J. A. GM-CSF in inflammation. J. Exp. Med. 217, e20190945 (2020). 31611249 10.1084/jem.20190945 PMC7037240 · DOI
  127. [161]Lee, K. M., Achuthan, A. A. & Hamilton, J. A. GM-CSF: A promising target in inflammation and autoimmunity. ImmunoTargets Ther. 9, 225–240 (2020). 33150139 10.2147/ITT.S262566 PMC7605919 · DOI
  128. [162]Martinez, M. & Moon, E. K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019). 30804938 10.3389/fimmu.2019.00128 PMC6370640 · DOI
  129. [163]Xie, C. et al. A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC). J. Clin. Oncol 41, TPS624 (2023). 10.1200/JCO.2023.41.4_suppl.TPS624 · DOI
  130. [164]Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189–1198 (2022). 35534566 10.1038/s41591-022-01800-8 PMC9205778 · DOI · Paper page
  131. [165]Kankeu Fonkoua, L. A., Sirpilla, O., Sakemura, R., Siegler, E. L. & Kenderian, S. S. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol. Ther. - Oncolytics 25, 69–77 (2022). 35434273 10.1016/j.omto.2022.03.009 PMC8980704 · DOI
  132. [166]Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471–482 (2019). 31715131 10.1016/j.ccell.2019.09.006 PMC7171534 · DOI · Paper page
  133. [167]Kuryk, L. et al. Novel insights into mesothelioma therapy: emerging avenues and future prospects. Front. Oncol. 12, 916839 (2022). 35785199 10.3389/fonc.2022.916839 PMC9247278 · DOI
  134. [168]Caruana, I. et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21, 524–529 (2015). 25849134 10.1038/nm.3833 PMC4425589 · DOI
  135. [169]Atsavapranee, E. S., Billingsley, M. M. & Mitchell, M. J. Delivery technologies for T cell gene editing: Applications in cancer immunotherapy. EBioMedicine 67, 103354 (2021). 33910123 10.1016/j.ebiom.2021.103354 PMC8099660 · DOI
  136. [170]Kamali, E., Rahbarizadeh, F., Hojati, Z. & Frödin, M. CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells. BMC Biotechnol. 21, 9 (2021). 33514392 10.1186/s12896-020-00665-4 PMC7844963 · DOI
  137. [171]Sackett, S. D. et al. Genetic engineering of immune evasive stem cell-derived islets. Transpl. Int. 35, 10817 (2022). 36545154 10.3389/ti.2022.10817 PMC9762357 · DOI · Paper page
  138. [172]Rosenberg, S. A. et al. Use of tumor-infiltrating Lymphocytes and Interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676–1680 (1988). 3264384 10.1056/NEJM198812223192527 · DOI · Paper page
  139. [173]Khawar, M. B. & Sun, H. CAR-NK cells: From natural basis to design for kill. Front. Immunol. 12, 707542 (2021). 34970253 10.3389/fimmu.2021.707542 PMC8712563 · DOI
  140. [174]Du, N., Guo, F., Wang, Y. & Cui, J. NK cell therapy: a rising star in cancer treatment. Cancers 13, 4129 (2021). 34439285 10.3390/cancers13164129 PMC8394762 · DOI
  141. [176]Chen, X., Jiang, L. & Liu, X. Natural killer cells: the next wave in cancer immunotherapy. Front. Immunol. 13, 954804 (2022). 35967421 10.3389/fimmu.2022.954804 PMC9364606 · DOI
  142. [177]Pang, Z., Wang, Z., Li, F., Feng, C. & Mu, X. Current progress of CAR-NK therapy in cancer treatment. Cancers 14, 4318 (2022). 36077853 10.3390/cancers14174318 PMC9454439 · DOI
  143. [178]Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat. Med. 30, 772–784 (2024). 38238616 10.1038/s41591-023-02785-8 PMC10957466 · DOI
  144. [179]Heipertz, E. L. et al. Current perspectives on “Off-The-Shelf” allogeneic NK and CAR-NK cell therapies. Front. Immunol. 12, 732135 (2021). 34925314 10.3389/fimmu.2021.732135 PMC8671166 · DOI
  145. [180]Tang, Y., Zhang, A. X. J., Chen, G., Wu, Y. & Gu, W. Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives. Mol. Ther. - Oncolytics 22, 410–430 (2021). 34553029 10.1016/j.omto.2021.07.006 PMC8430272 · DOI
  146. [181]Dafni, U. et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann. Oncol. 30, 1902–1913 (2019). 31566658 10.1093/annonc/mdz398 · DOI
  147. [182]Chandran, S. S. et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 18, 792–802 (2017). 28395880 10.1016/S1470-2045(17)30251-6 PMC5490083 · DOI
  148. [183]Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J. Clin. Oncol. 39, 2656–2666 (2021). 33979178 10.1200/JCO.21.00612 PMC8376325 · DOI
  149. [184]Rohaan, M. W. et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 387, 2113–2125 (2022). 36477031 10.1056/NEJMoa2210233 · DOI
  150. [186]Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target. Ther. 6, 412 (2021). 34897277 10.1038/s41392-021-00823-w PMC8666445 · DOI
  151. [187]Baulu, E., Gardet, C., Chuvin, N. & Depil, S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci. Adv. 9, eadf3700 (2023). 36791198 10.1126/sciadv.adf3700 PMC9931212 · DOI
  152. [188]D’Angelo, S. P. et al. SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. J. Clin. Oncol. 39, 11504 (2021). 10.1200/JCO.2021.39.15_suppl.11504 · DOI
  153. [189]Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419–425 (2021). 33558725 10.1038/s41591-020-01225-1 PMC9620481 · DOI
  154. [190]Sloas, C., Gill, S. & Klichinsky, M. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Front. Immunol. 12, 783305 (2021). 34899748 10.3389/fimmu.2021.783305 PMC8652144 · DOI
  155. [191]Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020). 32361713 10.1038/s41587-020-0462-y PMC7883632 · DOI · Paper page
  156. [192]Cheng, K. et al. Tumor‐associated macrophages in liver cancer: From mechanisms to therapy. Cancer Commun. 42, 1112–1140 (2022). 10.1002/cac2.12345 PMC9648394 36069342 · DOI
  157. [193]Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102–116 (2024). 38012418 10.1038/s41590-023-01687-8 · DOI
  158. [194]Zhang, L. et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J. Hematol. Oncol. J. Hematol. Oncol. 13, 153 (2020). 33176869 10.1186/s13045-020-00983-2 PMC7656711 · DOI
  159. [195]Wang, X. et al. Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nat. Commun. 14, 5778 (2023). 37723178 10.1038/s41467-023-41470-9 PMC10507032 · DOI
  160. [196]Xue, D. et al. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. Trends Biotechnol. 41, 907–922 (2023). 36858941 10.1016/j.tibtech.2023.02.003 · DOI
  161. [198]Annunziata, C. M. et al. Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. J. Clin. Oncol. 38, 3014 (2020). 10.1200/JCO.2020.38.15_suppl.3014 · DOI
  162. [199]Reiss, K. A. et al. A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors. J. Clin. Oncol. 40, 2533 (2022). 10.1200/JCO.2022.40.16_suppl.2533 · DOI
  163. [200]Kang, D. D., Li, H. & Dong, Y. Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics. Adv. Drug Deliv. Rev. 199, 114961 (2023). 37321375 10.1016/j.addr.2023.114961 PMC10264168 · DOI · Paper page
  164. [201]Miller, J. C. et al. Enhancing gene editing specificity by attenuating DNA cleavage kinetics. Nat. Biotechnol. 37, 945–952 (2019). 31359006 10.1038/s41587-019-0186-z · DOI
  165. [203]Chen, W. C. W. et al. A synthetic transcription platform for programmable gene expression in mammalian cells. Nat. Commun. 13, 6167 (2022). PMC9579178 36257931
  166. [204]Lundin, J. I. & Checkoway, H. Endotoxin and cancer. Environ. Health Perspect. 117, 1344–1350 (2009). 19750096 10.1289/ehp.0800439 PMC2737008 · DOI
  167. [205]Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020). 31848460 10.1038/s41571-019-0297-y PMC7223338 · DOI
  168. [206]Morgan, M. A., Lange, L. & Schambach, A. Prime time for base editing in the mitochondria. Signal Transduct. Target. Ther. 7, 213 (2022). PMC9259698 35794105
  169. [207]Kim, Y. G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl Acad. Sci. USA 93, 1156–1160 (1996). 8577732 10.1073/pnas.93.3.1156 PMC40048 · DOI
  170. [208]Ichikawa, D. M. et al. A universal deep-learning model for zinc finger design enables transcription factor reprogramming. Nat. Biotechnol. 41, 1117–1129 (2023). 36702896 10.1038/s41587-022-01624-4 PMC10421740 · DOI
  171. [209]Paschon, D. E. et al. Diversifying the structure of zinc finger nucleases for high-precision genome editing. Nat. Commun. 10, 1133 (2019). 30850604 10.1038/s41467-019-08867-x PMC6408524 · DOI
  172. [210]Kaina, B. A genome-wide screening for DNA repair genes: much more players than hitherto known. Signal Transduct. Target. Ther. 5, 204 (2020). 32934203 10.1038/s41392-020-00314-4 PMC7493888 · DOI
  173. [211]Ding, W. et al. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 20, 6495–6503 (2014). 10.1158/1078-0432.CCR-14-0250 25336692 · DOI
  174. [213]Wang, J. et al. Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res. 44, e30 (2016). PMC4756813 26527725
  175. [215]Baker, M. Gene-editing nucleases. Nat. Methods 9, 23–26 (2012). 22312637 10.1038/nmeth.1807 · DOI
  176. [216]Mock, U. et al. Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. Sci. Rep. 4, 6409 (2014). 25230987 10.1038/srep06409 PMC4166709 · DOI
  177. [218]Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017). 28123068 10.1126/scitranslmed.aaj2013 · DOI · Paper page
  178. [220]She, X. et al. Immune surveillance of brain metastatic cancer cells is mediated by IFITM1. EMBO J. 42, e111112 (2023). 36799040 10.15252/embj.2022111112 PMC10068327 · DOI
  179. [222]Chiu, D. K.-C. et al. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Gastroenterology159, 609–623 (2020). 32275969
  180. [223]Chen, Z. et al. In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184, 1262–1280.e22 (2021). 33636129 10.1016/j.cell.2021.02.019 PMC8054351 · DOI
  181. [224]Hu, Y. et al. Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin’s lymphoma: a first-in-human phase I study. EClinicalMedicine60, 102010 (2023). PMC10209187 37251628
  182. [225]Shakiba, M. et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J. Exp. Med. 219, e20201966 (2022). 34935874 10.1084/jem.20201966 PMC8704919 · DOI
  183. [226]Zhang, Y. et al. Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells. Nat. Commun. 14, 8491 (2023). 38123592 10.1038/s41467-023-44176-0 PMC10733396 · DOI
  184. [227]Tsujino, T. et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat. Commun. 14, 252 (2023). 36650183 10.1038/s41467-023-35880-y PMC9845315 · DOI
  185. [228]Vojnic, M. et al. Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. J. Thorac. Oncol. Publ. Int. Assoc. Study Lung Cancer 14, 802–815 (2019). PMC6486868 30831205
  186. [229]Chow, R. D. et al. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat. Neurosci. 20, 1329–1341 (2017). 28805815 10.1038/nn.4620 PMC5614841 · DOI
  187. [230]Ye, L. et al. In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nat. Biotechnol. 37, 1302–1313 (2019). 31548728 10.1038/s41587-019-0246-4 PMC6834896 · DOI
  188. [231]Dervovic, D. et al. In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer. Nat. Commun. 14, 3150 (2023). 37258521 10.1038/s41467-023-38841-7 PMC10232477 · DOI
  189. [232]Lu, Y. et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat. Med. 26, 732–740 (2020). 32341578 10.1038/s41591-020-0840-5 · DOI
  190. [233]Deng, L. et al. Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. Cell Death Discov. 9, 1–10 (2023). 36725843 10.1038/s41420-023-01315-2 PMC9892530 · DOI
  191. [234]Wei, L. et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat. Commun. 10, 4681 (2019). 31615983 10.1038/s41467-019-12606-7 PMC6794322 · DOI · Paper page
  192. [235]Li, L. et al. In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma. Cell Death Discov. 9, 1–11 (2023). 37666810 PMC10477178
  193. [236]Benichou, E. et al. The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolism. Nat. Commun. 15, 1879 (2024). 38424041 10.1038/s41467-024-45548-w PMC10904844 · DOI
  194. [237]Porto, E. M., Komor, A. C., Slaymaker, I. M. & Yeo, G. W. Base editing: advances and therapeutic opportunities. Nat. Rev. Drug Discov. 19, 839–859 (2020). 33077937 10.1038/s41573-020-0084-6 PMC7721651 · DOI
  195. [240]Rees, H. A. et al. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat. Commun. 8, 15790 (2017). 28585549 10.1038/ncomms15790 PMC5467206 · DOI
  196. [241]Komor, A. C. et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci. Adv. 3, eaao4774 (2017). 28875174 10.1126/sciadv.aao4774 PMC5576876 · DOI
  197. [242]Webber, B. R. et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat. Commun. 10, 5222 (2019). 31745080 10.1038/s41467-019-13007-6 PMC6864045 · DOI · Paper page
  198. [243]Sayed, S. et al. Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing. Cancer Res 82, 3002–3015 (2022). 35802645 10.1158/0008-5472.CAN-21-2519 PMC9437569 · DOI
  199. [244]Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019). 31634902 10.1038/s41586-019-1711-4 PMC6907074 · DOI · Paper page
  200. [245]Chen, P. J. & Liu, D. R. Prime editing for precise and highly versatile genome manipulation. Nat. Rev. Genet. 24, 161–177 (2023). 36344749 10.1038/s41576-022-00541-1 PMC10989687 · DOI

200 of 436 shown

Cited by

Sorted by citations

Authors
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y.
Affiliations
  • University of Hong Kong - Shenzhen Hospital (CN)
  • University of Hong Kong (HK)
  • Jinan University (CN)
Corresponding author
Guan, Xin-Yuan
ORCID
Venue
Signal Transduction and Targeted Therapy
Publisher
Springer Science and Business Media LLC
Published
2024-07-17
Volume
9
Issue
1
Pages
175-175
ISSN
2059-3635 (ISSN-L)
DOI
10.1038/s41392-024-01856-7
PMC
PMC11252281
OpenAlex
W4400748356
Cited by
1,201
References
39
Citations by year
2026: 510 · 2025: 648 · 2024: 41 · 2022: 1
FWCI
89.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
cancer therapy, targeted therapy, antibody-drug conjugates, cell therapy, gene therapy, peptide therapeutics, antibody drugs, personalized medicine, chemotherapy, radiotherapy
MeSH terms
Antineoplastic Agents, Humans, Neoplasms, Genetic Therapy, Immunoconjugates, Molecular Targeted Therapy, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review